BPMC Stock Cash Flow Statements

Blueprint Medicines Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Blueprint Medicines Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31

cash flows from operating activities
net income	496,000	-49,956,000	-56,274,000	-49,995,000	89,136,000	-110,916,000	-133,714,000	-132,794,000	-129,560,000	-158,646,000	-133,162,000	-159,710,000	-105,999,000	-318,686,000	-117,240,000	-108,445,000	-99,714,000	-85,668,000	633,978,000	-123,473,000	-110,955,000	-66,331,000	-94,275,000	-99,681,000	-87,407,000	-80,322,000	-72,723,000	-27,048,000	-56,549,000		-37,703,000	-61,361,023	-27,977		34,346,768	-18,894,000	-15,504,000	-15,575,000	-12,642,000	-12,980,000	-11,572,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	4,459,000	4,001,000	3,863,000	3,617,000	4,810,000	1,531,000	2,872,000	3,578,000	3,684,000	7,016,000	1,621,000	1,470,000	1,628,000	1,663,000	1,616,000	1,592,000	1,608,000	1,672,000	1,648,000	1,668,000	1,571,000	-2,075,000	2,605,000	2,510,000	2,219,000	1,170,000	1,163,000	1,133,000	780,000		396,000	790,602	398		-780,811	396,000	386,000	333,000	204,000	202,000	209,000
non-cash lease expense	2,592,000	2,544,000	2,523,000	2,454,000	2,404,000	2,350,000	2,302,000	2,255,000	2,202,000
stock-based compensation	29,056,000	28,382,000	28,282,000	28,022,000	24,225,000	22,585,000	23,070,000	23,821,000	23,196,000	26,116,000	24,109,000	25,347,000	23,399,000	22,681,000	23,958,000	24,307,000	20,684,000	19,504,000	19,635,000	19,528,000	16,859,000	15,699,000	14,993,000	13,666,000	10,295,000	8,832,000	8,391,000	7,762,000	5,549,000		3,599,000	5,216,760	2,240		-2,584,506	1,487,000	1,102,000	1,195,000	971,000	2,174,000	840,000
non-cash interest expense	776,000	401,000	-345,000	335,000	793,000	2,252,000	3,589,000	3,662,000	4,635,000	7,410,000
net (accretion of discount) amortization of premium on investments	-3,332,000	-5,293,000	-6,334,000	-5,645,000	-5,193,000
non-cash debt extinguishment gain		0	0	-18,000	-173,658,000
equity investment gain	-50,039,000
other	-141,000	695,000	-816,000	-34,000	-827,000	-1,195,000	5,953,000	-2,914,000	-697,000	1,835,000	237,000	-263,000	813,000	702,000	1,325,000	816,000	536,000	101,000	59,000
changes in assets and liabilities:
accounts receivable	-1,397,000	-10,329,000	19,891,000	-25,068,000	-17,339,000	-1,745,000	-5,865,000	-8,156,000	-4,949,000	-3,981,000	7,681,000	1,517,000	-3,645,000	-6,768,000	7,032,000	9,206,000	-27,613,000	37,318,000	-40,965,000	1,107,000	-3,847,000	1,751,000	-1,664,000
inventory	187,000	2,029,000	-4,065,000	-4,686,000	2,696,000	829,000	2,917,000	-8,190,000	78,000	11,731,000	-5,959,000	-4,866,000	-9,828,000	-749,000	-7,270,000	295,000	-4,837,000	-2,216,000	-1,743,000	-2,366,000	-382,000
prepaid expenses and other current assets	-961,000	4,720,000	-619,000	-7,747,000	1,016,000	5,655,000	-4,127,000	-4,063,000	5,741,000	-1,363,000	739,000	3,274,000	-19,588,000	6,488,000	-1,040,000	1,839,000	-2,594,000	-5,354,000	1,893,000	-7,751,000	-1,408,000	3,837,000	-2,335,000	-2,917,000	-1,923,000	-137,000	3,333,000	-385,000	3,473,000		2,436,000	-2,606,028	-1,972		-1,942,290	-319,000	2,262,000	-438,000	-405,000	-275,000	-364,000
other assets	-8,876,000	-1,558,000	-595,000	-4,645,000	-4,332,000	-2,987,000	-305,000	-1,002,000	-417,000	-4,434,000	1,302,000	553,000	-13,741,000	1,056,000	987,000	-3,785,000	-44,000	-356,000	-222,000	2,084,000	-66,000	78,000	121,000	-65,000	-114,000	23,000	-681,000	-3,557,000	-27,000		-804,000	3,986	14			-28,000	11,000	3,000	-524,000
accounts payable	-6,044,000			-82,000	313,000	-2,364,000	26,000	-3,588,000	7,806,000	-3,785,000	-8,620,000	-2,927,000	9,516,000	-923,000	7,688,000	-1,080,000	-1,464,000	1,187,000	-2,780,000	-2,913,000	3,715,000	2,543,000	-4,386,000	2,309,000	982,000	-689,000	1,029,000	-303,000	-482,000		-422,000	296,929	71		-427,373	-140,000	567,000	707,000	-97,000	-736,000	1,517,000
accrued expenses	-13,552,000			20,768,000	-25,826,000	16,175,000	10,594,000	-2,008,000	-23,686,000	1,535,000	7,392,000	17,490,000	-17,049,000	18,939,000	-11,800,000	19,741,000	-20,785,000	14,641,000	6,146,000	12,003,000	-16,576,000	10,572,000	16,414,000	11,202,000	-1,208,000	5,878,000	7,331,000	12,120,000	-525,000		5,123,000	3,954,552	-1,552		-2,200,073	2,523,000	-321,000	412,000	1,088,000	571,000	-115,000
deferred revenue and other long-term liabilities	-4,500,000
operating lease liabilities	-3,203,000	-3,100,000	-3,034,000	-2,940,000	-2,889,000	-2,789,000	-2,682,000	-2,604,000	-2,556,000	-2,332,000	-1,974,000	-1,911,000	-1,879,000	-2,099,000	-2,011,000	-1,940,000	-1,905,000	-1,776,000	-1,752,000	-1,787,000	-1,073,000	61,000	-591,000	-596,000	-969,000
net cash from operating activities	-54,479,000	-29,364,000	-13,637,000	-48,072,000	-101,513,000	-78,928,000	-104,483,000	-130,475,000	-122,961,000	-121,405,000	-129,890,000			-14,114,000	-95,596,000	-63,165,000	-125,778,000	-24,799,000	622,326,000	-101,164,000	-109,328,000	-44,895,000	-71,704,000	-81,228,000	-80,188,000	-67,582,000	-55,005,000	-2,859,000	-49,563,000	-34,750,000	-26,518,000	-58,565,920	-31,080	-24,507,284	-12,923,716	-17,833,000	30,751,000	-13,046,000	-12,465,000	-11,055,000	4,890,000
capex	-1,831,000	-932,000	-25,000	-2,569,000	-1,104,000	-4,673,000	-6,251,000	-2,554,000	-2,584,000	-1,481,000	-3,729,000			-1,258,000	-996,000	-662,000	-173,000	-687,000	-6,000	-941,000	-1,525,000	-3,891,000	-6,182,000	-2,170,000	-1,770,000	-425,000	-2,618,000	-3,322,000	-6,312,000	0	-4,475,000	-456,790	-210	0	1,811,664	-552,000	-1,262,000	-3,754,000	-822,000	-288,000	-19,000
free cash flows	-56,310,000	-30,296,000	-13,662,000	-50,641,000	-102,617,000	-83,601,000	-110,734,000	-133,029,000	-125,545,000	-122,886,000	-133,619,000			-15,372,000	-96,592,000	-63,827,000	-125,951,000	-25,486,000	622,320,000	-102,105,000	-110,853,000	-48,786,000	-77,886,000	-83,398,000	-81,958,000	-68,007,000	-57,623,000	-6,181,000	-55,875,000	-34,750,000	-30,993,000	-59,022,710	-31,290	-24,507,284	-11,112,052	-18,385,000	29,489,000	-16,800,000	-13,287,000	-11,343,000	4,871,000
cash flows from investing activities
purchases of property and equipment	-1,831,000	-932,000	-25,000	-2,569,000	-1,104,000	-4,673,000	-6,251,000	-2,554,000	-2,584,000	-1,481,000	-3,729,000	-2,556,000	-1,153,000	-1,258,000	-996,000	-662,000	-173,000	-687,000	-6,000	-941,000	-1,525,000	-3,891,000	-6,182,000	-2,170,000	-1,770,000	-425,000	-2,618,000	-3,322,000	-6,312,000		-4,475,000	-456,790	-210		1,811,664	-552,000	-1,262,000	-3,754,000	-822,000	-288,000	-19,000
purchases of investments	-283,327,000	-209,769,000	-201,024,000	-355,473,000	-200,165,000	-117,658,000	-240,935,000	-274,895,000	-132,875,000	-231,051,000	-218,717,000	0	-39,937,000	-140,543,000	-132,262,000	-299,564,000	-83,080,000	-172,457,000	-564,832,000	-92,898,000	-139,250,000	-140,873,000	-132,225,000	-352,373,000	-112,916,000	-152,334,000	-159,617,000	-150,469,000	-338,816,000		-105,396,000	-209,873,997	-18,003		69,116,682	0	-69,222,000
maturities of investments	271,500,000	244,410,000	231,000,000	169,750,000	278,400,000	201,100,000	237,600,000	309,515,000	308,250,000	179,250,000	90,500,000			52,999,000	237,331,000	185,050,000	215,450,000	97,612,000	134,700,000	105,400,000	200,635,000	212,500,000	212,944,000	106,490,000	204,000,000	209,000,000	178,825,000	139,000,000	126,000,000		102,000,000	95,946,000	54,000		-5,973,000
proceeds from sale of equity investment	78,737,000
net cash from investing activities	65,079,000	33,709,000	29,951,000	-188,292,000	77,131,000	78,769,000	-9,586,000	32,066,000	172,791,000	-53,283,000	-132,235,000	77,067,000	-41,090,000	-346,954,000	104,073,000	-115,176,000	132,197,000	-75,532,000	-430,138,000	11,561,000	59,860,000	67,736,000	74,537,000	-248,053,000	89,314,000				-219,128,000				35,787	-218,621,465	64,836,465	5,448,000	-70,365,000	-3,684,000	-822,000	-288,000	-1,285,000
cash flows from financing activities
proceeds from at-the-market offerings, net of issuance costs		0	0	0	48,936,000
net proceeds from stock option exercises and employee stock purchase plan	13,298,000	9,759,000	18,377,000	31,211,000	18,396,000	15,607,000	431,000			2,510,000	1,924,000	2,498,000	1,264,000	17,929,000	10,922,000	14,854,000	7,011,000	25,344,000	5,035,000				4,543,000
principal payments for financing arrangements	-4,106,000		0	-172,000	-369,000
net cash from financing activities	9,192,000	9,759,000	18,377,000	178,012,000	66,963,000	15,528,000	98,399,000			2,491,000	380,557,000	177,498,000	1,264,000	17,929,000	10,922,000	14,854,000	7,011,000	220,093,000	84,341,000	3,175,000	310,150,000	1,834,000	4,495,000	332,298,000	2,011,000	764,000	113,000	515,000	3,062,000	327,853,000	372,000	215,723,420	-420	132,579,053	1,319,947	-518,000	-804,000	-343,000	-520,000	154,632,000	-547,000
net increase in cash, cash equivalents, and restricted cash	19,792,000	14,104,000	34,691,000	-58,352,000	42,581,000				49,830,000	-172,197,000			-172,552,000	-343,139,000	19,399,000	-163,487,000	13,430,000	119,762,000	276,529,000	-86,428,000	260,682,000	24,675,000	7,328,000	3,017,000	11,137,000	-10,577,000	-38,302,000	-17,135,000	-265,629,000
cash, cash equivalents and restricted cash at beginning of period	113,639,000	0	0	0	81,524,000	0	0	0	124,904,000	0	0	0	215,119,000	0	0	0	689,804,000	0	0	0	119,604,000	0	0	0	73,429,000
effect of exchange rate changes on cash, cash equivalents and restricted cash	661,000	-1,324,000	591,000	-31,000	-145,000	487,000	-541,000	59,000	197,000	478,000	-379,000	-109,000	-197,000	-506,000	-123,000	-162,000	-97,000	-347,000	14,000	-62,000	50,000	28,000	-13,000	19,000	-16,000
cash, cash equivalents and restricted cash at end of period	134,092,000	12,780,000	35,282,000	-58,383,000	123,960,000	15,856,000	-16,211,000	-93,052,000	174,931,000	-171,719,000	118,053,000	136,200,000	42,370,000	-343,645,000	19,276,000	-163,649,000	703,137,000	119,415,000	276,543,000	-86,490,000	380,336,000	24,703,000	7,315,000	3,036,000	84,550,000
supplemental cash flow information
cash paid for interest	21,465,000	23,797,000	23,437,000	18,338,000	14,280,000	13,012,000	10,288,000	8,083,000	7,084,000	6,858,000												0	1,000	2,000	2,000	206,000	30,000	13,000	18,000		34,000	90,950	50		-179,746	85,000	95,000	105,000	111,000	116,000	120,000
property and equipment purchases unpaid at period end	698,000	319,000	66,000	-1,794,000	1,834,000	-1,365,000	-682,000			129,000	-1,634,000	793,000	1,036,000	-57,000	-24,000	-213,000	443,000	-68,000	93,000	-349,000	465,000	-2,267,000	-103,000	1,850,000	1,478,000	784,000	-1,986,000	-1,012,000	3,126,000		1,276,000	1,919,920	80
cash paid for taxes	703,000		235,000	34,000	520,000		86,000	365,000	311,000	2,487,000	3,247,000	602,000	169,000	20,000	76,000	24,000	574,000	710,000	21,000	15,000	32,000	55,000	33,000
non-cash customer consideration										0
unbilled accounts receivable						42,000	2,728,000	392,000	9,899,000	-13,086,000	-309,000	1,556,000	8,035,000	-553,000	2,445,000	-4,567,000	9,013,000	-1,326,000	3,990,000	-280,000	2,152,000	-20,180,000	1,946,000								-360,000	501,249	751		-63,041	881,000	-818,000	-944,000	-547,000	-1,439,000	-484,000
other long term liabilities
deferred revenue		-2,970,000	-63,000	-534,000	3,158,000	-2,407,000	-317,000	1,136,000	-11,099,000	15,139,000	-5,514,000	-1,187,000	-13,251,000	1,179,000	-2,881,000	-2,695,000	-185,000	-4,249,000	702,000	-793,000	-575,000	4,742,000	-3,139,000	-966,000	-731,000	-1,033,000	-1,095,000	8,561,000	-954,000		-4,633,000	-5,826,985	-3,015		-39,374,293	-3,715,000	43,127,000	-1,220,000	-957,000	986,000	14,832,000
net proceeds from term loan facility		0	0			-35,000				-11,000
net proceeds from the sale of future royalties and revenues										-8,000
principle payments for financing arrangements
cash paid (refunds received) for taxes
accrued expenses and accounts payable
other long-term liabilities			-4,325,000				3,000	0	-7,238,000		-427,000	-669,000	6,826,000
acquired in-process research and development
purchase of in-process research and development asset, net of cash acquired
net decrease in cash, cash equivalents, and restricted cash
net (accretion of discount) amortization of premium on marketable securities
gross proceeds from the sale of future royalties
debt issuance costs incurred but unpaid at period end
noncash lease expense												2,070,000	2,037,000	1,638,000	1,595,000	1,551,000	1,522,000	1,502,000	1,466,000	1,432,000	1,391,000
accretion of premiums and discounts on investments																		221,000	271,000	108,000	-134,000	-583,000	-1,393,000	-1,641,000	-1,332,000	-1,447,000	-1,259,000	-983,000	-692,000		-110,000	75,914	86		-109,796	75,000	35,000
proceeds from common stock offerings, net of issuance costs
proceeds from issuance of common stock related to collaboration agreement
net cash provided used in operating activities													-132,726,000
other financing activities																						0	-44,000	-44,000	-28,000
proceeds from public offerings of common stock, net of issuance cost																			0
issuance of common stock related to collaboration agreement
payment of offering costs																										0	0	-117,000	-164,000		-207,000	-715,511	-489					0	-81,000	-1,819,000	-146,000
public offering costs incurred but unpaid at period end																			1,000	-113,000	118,000		-3,000						166,000		-206,000	305,484	516							-777,000	805,000
deferred rent																										-186,000	-151,000	-163,000	-140,000		5,952,000	369,135	-135		236,645	-119,000	-118,000	2,456,000			-40,000
principal payments on loan payable																										-278,000	-417,000	-416,000	-417,000		-583,000	-1,416,167	-833		1,664,500	-834,000	-833,000	-556,000	-417,000	-416,000	-417,000
proceeds from common stock offerings, net of issurance costs
proceeds from public offerings of common stock, net of commissions, underwriting discounts and offering costs																					308,541,000
proceeds from issuance of common stock																					1,609,000				2,039,000																19,000
proceeds from public offerings of common stock, net of commissions and underwriting discounts
proceeds from public offering of common stock, net of issuance cost																							-284,000
principal payments on capital lease obligations																										-42,000	-81,000
operating activities
investing activities
net cash from by investing activities																											16,590,000
financing activities
proceeds from public offering of common stock, net of commissions and underwriting discounts																															0
proceeds from issuance of common stock, net of repurchases																											611,000	1,087,000	3,643,000		1,162,000	1,655,098	902		-344,553	316,000	29,000	213,000	-22,000
cash, cash equivalents, and restricted cash at beginning of period																											0	0	405,072,000
cash, cash equivalents, and restricted cash at end of period																											-38,302,000	-17,135,000	139,443,000
noncash interest expense																												4,000	4,000		8,000	18,989	11		-41,941	20,000	22,000	25,000	26,000	29,000	29,000
net increase in cash and cash equivalents																														342,975,000	-34,017,000	39,272,713	4,287	-110,549,696	53,232,696	-12,903,000	-40,418,000	-17,073,000	-13,807,000	143,289,000	3,058,000
restricted cash																															0				-118,881	0	119,000	70,000	0	0	-1,266,000
net cash (used in) investing activities																															-7,871,000
cash and cash equivalents at beginning of period																															0	52,016,931	52,069		-162,544,293	0	162,707,000	0	0	0	47,240,000
cash and cash equivalents at end of period																															-34,017,000	91,289,644	56,356		-109,311,597	-12,903,000	122,289,000	-17,073,000	-13,807,000	143,289,000	50,298,000
change in fair value of warrant liability																																						0	0	407,000	38,000
proceeds from ipo, net of commissions and underwriting discounts																																						0	0
property and equipment purchases incurred but unpaid at period end																																			-115,985	-128,000	244,000	-1,564,000	2,793,000
conversion of convertible preferred stock into common stock																																						0	0
reclassification of warrant liability to additional paid-in-capital																																						0	0
proceeds from issuance of series c convertible preferred stock, net of issuance costs
proceeds from term loan
proceeds from issuance of series a convertible preferred stock, net of issuance costs
proceeds from issuance of series b convertible preferred stock, net of issuance costs
debt issuance costs
issuance of warrants in connection with term loan
adjustments to reconcile net income to net cash from in operating activities:
series c convertible preferred stock issuance costs

We provide you with 20 years of cash flow statements for Blueprint Medicines stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Blueprint Medicines stock. Explore the full financial landscape of Blueprint Medicines stock with our expertly curated income statements.

The information provided in this report about Blueprint Medicines stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.